Rapport Therapeutics’ IPO came with a concurrent private placement that boosted the biotech’s cash haul. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.
The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News.
Recent Posts
Categories
Related Articles
When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This
Meditech is integrating Suki’s AI assistant into more than a dozen rural...
FTC to sue PBMs over insulin pricing and rebates
From the FTC’s press release out today: Today, the Federal Trade Commission...
World Mental Health Day 2024
Every year, World Mental Health Day is an opportunity for mental health...
North Carolina’s Effort to Relieve Medical Debt
This policy watch examines the burden of medical debt in North Carolina...
Leave a comment